Clarivate Epidemiology’s coverage of PV comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France, Germany, Italy, Spain, the United Kingdom, and Japan). We report both the diagnosed incidence and prevalence of PV for each country, as well as annualized case counts projected to the national population.
Clarivate Epidemiology’s forecast will answer the following questions:
How many people in each of the major mature pharmaceutical markets have been formally diagnosed with PV; how many are newly diagnosed each year?
How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of PV over the forecast period?
All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.
In total, Clarivate Epidemiology forecasts three patient populations, as follows:
Diagnosed Prevalence of Pemphigus Vulgaris per 100,000 People in 2021 and 2041
Relative Sizes of the Contributing Factors to the Trend in Diagnosed Prevalent Cases of Pemphigus Vulgaris over the Next 20 Years
Epidemiology Data
Methods
Diagnosed Incident Cases
Diagnosed Prevalent Cases
Diagnosed Incident Cases by Severity
Reference Materials
Literature Review
Studies Included in the Analysis of Pemphigus Vulgaris
Studies Excluded from the Analysis of Pemphigus Vulgaris
Risk/Protective Factors
Risk/Protective Factors for Pemphigus Vulgaris
Bibliography
Abbreviations
Glossary
Mudasir Khan, M.P.H.
Mudasir Khan, M.P.H., is a senior epidemiologist at Clarivate. His areas of expertise are oncology and psychiatry diseases. He holds a master’s degree in public health from the Tata Institute of Social Sciences in Mumbai.
Alison Isherwood, M.Sc., M.Res., Ph.D.
Alison Isherwood, M.Sc., M.Res., Ph.D., is a senior director on the Epidemiology team at Clarivate. She specializes in female cancers, biomarker, and infectious disease epidemiology, particularly involving the impact of vaccination. She holds a B.Sc. in medical microbiology, a master’s degree in research in the life sciences (specializing in virology and parasitology), and an M.Sc. in epidemiology, all from the University of Edinburgh. She also holds a Ph.D. in molecular virology from the University of Reading in England.
